title: Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results.
abstract: OBJECTIVE
  Cholangiocarcinoma (CCA) is considered a contraindication for liver transplantation by most liver transplant centers. The aim of this study has been to report our results as well as to explore factors that influence patient survival after liver transplantation for CCA.
  
  
  METHODS
  All transplant patients with CCA in Norway, Sweden and Finland during 1984-2005 were included (n = 53). Thirty-three patients (62%) had intrahepatic CCA. Twenty-one patients (40%) had a more advanced tumor (>TNM stage 2). Thirty-four of the 53 recipients (64%) had primary sclerosing cholangitis (PSC).
  
  
  RESULTS
  Patients with TNM stage ≤ 2 transplanted after 1995 had a 5-year survival rate of 48%. The overall 5-year patient survival rate was 25%. There was no difference in survival between patients with extrahepatic and intrahepatic CCA. The 5-year survival rate among patients with TNM stage ≤ 2 was 36%. Patients with TNM stage >2 had a 10% 5-year survival rate; the difference was significant at p < 0.01. Patients transplanted after 1995 had a significantly better 5-year survival rate than pre-1995 patients (38% vs. 0%, p < 0.01). Patients transplanted after 1995 with TNM ≤ 2 and CA 19-9 ≤ 100 had the 5-year survival of 58%.
  
  
  CONCLUSIONS
  By selecting CCA patients with TNM stage ≤ 2 and a CA 19-9 ≤ 100 a reasonable 5-year survival rate is possible. We think that CCA in selected cases can be an acceptable indication for liver transplantation.
authors.affiliation: Transplant Institute, Sahlgrenska University Hospital, Göteborg, Sweden. styrbjorn.friman@surgery.gu.se
authors.forename: Styrbjörn
authors.initials: S
authors.lastname: Friman
authors.forename: Aksel
authors.initials: A
authors.lastname: Foss
authors.forename: Helena
authors.initials: H
authors.lastname: Isoniemi
authors.forename: Michael
authors.initials: M
authors.lastname: Olausson
authors.forename: Krister
authors.initials: K
authors.lastname: Höckerstedt
authors.forename: Shinji
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Tom Hemming
authors.initials: TH
authors.lastname: Karlsen
authors.forename: Magnus
authors.initials: M
authors.lastname: Rizell
authors.forename: Bo-Göran
authors.initials: BG
authors.lastname: Ericzon
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery*; D018395:CA-19-9 Antigen / Q000032:analysis; D018281:Cholangiocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015209:Cholangitis, Sclerosing / Q000150:complications / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012042:Registries; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018395:CA-19-9 Antigen